Comparative Pharmacology
Head-to-head clinical analysis: ALCAFTADINE versus BEPREVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAFTADINE versus BEPREVE.
ALCAFTADINE vs BEPREVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Bepotastine besilate is a selective histamine H1 receptor antagonist. It inhibits histamine-induced vascular permeability, pruritus, and conjunctival inflammation.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
1 drop in the affected eye(s) twice daily (approximately every 6-8 hours).
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Plasma elimination half-life is approximately 2-3 hours in healthy adults. In patients with renal impairment, half-life may be prolonged (up to 6-8 hours in severe impairment).
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Bepotastine besilate is primarily excreted via renal elimination. Approximately 75-80% of the administered dose is eliminated unchanged in the urine, with less than 10% recovered in feces. Minor biliary excretion occurs.
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."